RCC Ablation Technique Influences Survival Time
One type thermal ablation appeared superior for cT1 a renal cell carcinoma patients.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
Sunitinib Timing for mRCC Does Not Affect CN Complication Rates
Investigators observed no differences in surgery time, blood loss, and hospital stay, with deferred vs upfront cytoreductive nephrectomy.
Partial Nephrectomy Preferable for T1a RCC
In a population-based study, PN was associated with improved cancer-specific survival by 56%.
PN, RN Offer Comparable Long-Term Survival for T1b RCC
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Targeted RCC Therapies Benefit ‘Real World’ Medicare Patients
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCC
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Nivolumab and Ipilimumab Combo Shows Promise in Advanced RCC With Brain Metastases
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Inactivating Mutations in Genes Encoding for Components of the mSWI/SNF Complex May Be Associated With Improved OS in Immunotherapy-Treated Patients
The identification of biomarkers of response and resistance to immune checkpoint inhibitors remains an active area of research.
Rise in TSH: A Prognostic Indicator in Sunitinib-Treated Metastatic RCC?
In this study, more than 40% of patients with metastatic RCC showed signs of hypothyroidism following 2 weeks of treatment with sunitinib.
Checkpoint Inhibitor-Based Combination Prolonged Progression in RCC
No overall survival benefit has yet been seen with the regimen in RCC.
Percutaneous Ablation Appropriate for Localized Renal Tumors
Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.
Bavencio Plus Inlyta Approved as First-Line Tx for Advanced Renal Cell Carcinoma
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Elevated CRP Before RCC Surgery Predicts Renal Function Decline
Elevated C-reactive protein levels prior to nephrectomy for renal cell carcinoma is associated with an increased risk of renal impairment, a study found.
Left-Sided RCC Linked to Worse Cancer-Specific Survival
In a study, left-sided renal cell carcinoma (RCC) was associated with a 15% to 20% increased risk of dying from the malignancy compared with right-sided RCC.
FDA Approves New First-Line Treatment for Advanced RCC
FDA approved pembrolizumab, a PD-1 inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma.
Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Want to read more?
Please login or register first to view this content.
